Loading stock data…
$2.31-0.32 (-12.00%)
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Niki BioSolutions, Inc. in the Healthcare sector is trading at $2.31 with a market capitalization of $5M. The stock is currently near its 52-week low of $2.31, remaining 71.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q4 2024 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | — | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$825,131↓ | -$589,631 | — | $558,599 |
| Net Income | -$307,495↑ | -$613,995 | — | -$919,900 |
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline...